Breaking News

Quotient Clinical Extends Translational Pharmaceutics Platform

April 24, 2014

Will support cancer drug development programs

Quotient Clinical has extended its Translational Pharmaceutics platform into cancer drug development, employing its real-time manufacturing capabilities to supply drug products to support first-in-patient and proof-of-concept programs.
Translational Pharmaceutics integrates real-time drug product manufacturing and clinical testing, using processes designed to reduce the timelines and cost of early stage drug development. Quotient has applied this platform in early development programs at its own manufacturing and clinical facilities in Nottingham, UK.
Quotient’s real-time manufacturing approach offers a number of advantages in this setting, including:flexibility of drug product manufacturing in response to patient recruitment rates, with product typically being supplied in less than three weeks,customization of drug product dose and/or composition according to patient/study need, and in response to clinical data emerging from the on-going program;and increased efficiency of drug substance consumption.
Mark Egerton, chief executive officer of Quotient Clinical, said, “Approximately 30% of the industry’s drug development pipeline is focused on cancer. We have developed our real-time manufacturing and supply capabilities to support this specialist area with first-in-patient and proof-of-concept programs. We have already supported multiple development programs in the UK and mainland Europe, and will shortly be embarking on a similar project in North America. In these, and other future programs, we will be helping our clients to accelerate their early development pipelines and increase overall R&D productivity.”
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer